Basilea Pharmaceutica (BPMUF) Stock Price, News & Analysis

Company Overview

Basilea Pharmaceutica Ltd. is a Switzerland-based biopharmaceutical company focused on developing and commercializing medicines for serious bacterial and fungal infections. The company’s portfolio is intended primarily for use in hospitals and other specialized-care settings where drug-resistant pathogens and complex infections present significant treatment challenges.

Basilea’s key products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), a cephalosporin antibiotic used for certain serious bacterial infections. The company also conducts research and development in anti-infective therapies and works with commercial partners to expand the availability of its products.

Founded in 2000 as a spin-off from Roche, Basilea is headquartered in Basel, Switzerland. Its medicines are marketed in multiple international regions through a combination of its own commercial activities and licensing or distribution partnerships. Basilea’s leadership includes Chief Executive Officer Marc Gitzinger, who has led the company since 2010.

Key Stats

• Today's Range: $76.25 to $76.25
• 50-Day Range: $60.28 to $77.40
• 52-Week Range: $59.29 to $77.40
• Volume: 10 shs
• Average Volume: 1 shs
• Market Capitalization: $1.00 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 10/04/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:BPMUF
• CIK: N/A
• Web: www.basilea.com
• Phone: (161) 606-1111
• Fax: 41-61-606-1112
• Employees: 189
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $280.43 million
• Price / Sales: 3.58
• Cash Flow: $3.85 per share
• Price / Cash Flow: 19.81
• Book Value: $11.73 per share
• Price / Book: 6.50

Miscellaneous

• Outstanding Shares: 13,170,000
• Free Float: N/A
• Market Cap: $1.00 billion
• Optionable: Not Optionable
• Beta: 0.22